Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells
Phytomedicine · 2024-02 · 124 · 155308
DOI: 10.1016/j.phymed.2023.155308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024-02. Verfasst von Songbin Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, National Key Clinic of Pain Medicine, Shenzhen Nanshan People's …. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Lanatosides. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanming Project of Medicine in Shenzen Municipality.
Abstract (Originalsprache)
BACKGROUND: In the past decades, extensive research has been conducted to identify new drug targets for the treatment of Herpes simplex virus type 1 (HSV-1) infections. However, the emergence of drug-resistant HSV-1 strains remains a major challenge. This necessitates the identification of new drugs with novel mechanisms of action. Lanatoside C (LanC), a cardiac glycoside (CG) approved by the US Food and Drug Administration (FDA), has demonstrated anticancer and antiviral properties. Nevertheless, its potential as an agent against HSV-1 infections and the underlying mechanism of action are currently unknown. PURPOSE: This study aimed to investigate the antiviral activity of LanC against HSV-1 and elucidate its molecular mechanisms. METHODS: The in vitro antiviral activity of LanC was assessed by examining the levels of viral genes, proteins, and virus titers in HSV-1-infected ARPE-19 and Vero cells. Immunofluorescence (IF) analysis was performed to determine the intracellular distribution of NRF2. Additionally, an in vivo mouse model of HSV-1 infection was developed to evaluate the antiviral activity of LanC, using indicators such as intraepidermal nerve fibers (IENFs) loss and viral gene inhibition. RESULTS: Our findings demonstrate that LanC significantly inhibits HSV-1 replication both in vitro and in vivo. The antiviral effect of LanC is mediated by the perinuclear translocation of NRF2. CONCLUSIONS: LanC exhibits anti-HSV-1 effects in viral infections, which are associated with the intracellular translocation of NRF2. These findings suggest that LanC has the potential to serve as a novel NRF2 modulator in the treatment of viral diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, National Key Clinic of Pain Medicine, Shenzhen Nanshan People's Hospital, and the 6th Affiliated Hospital of Shenzhen University Healt…
- Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Förderung
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Wu, S., Wang, S., Lin, X., Yang, S., Ba, X., Xiong, D., Xiao, L., & Li, R. (2024). Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells. Phytomedicine, 124, 155308. https://doi.org/10.1016/j.phymed.2023.155308
Vancouver
Wu S, Wang S, Lin X, Yang S, Ba X, Xiong D, et al. Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells. Phytomedicine. 2024;124:155308. doi:10.1016/j.phymed.2023.155308
BibTeX
@article{Wu2024,
author = {Wu, Songbin and Wang, Sashuang and Lin, Xiaomian and Yang, Shaomin and Ba, Xiyuan and Xiong, Donglin and Xiao, Lizu and Li, Rongzhen},
title = {Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells},
journal = {Phytomedicine},
year = {2024},
volume = {124},
pages = {155308},
doi = {10.1016/j.phymed.2023.155308}
}
EUVIMED